Moletest Clinical Evaluation 004
Research type
Research Study
Full title
A hospital-based study of a novel photographic image analysis system to discriminate benign pigmented skin lesions from those considered suspect for melanoma.
IRAS ID
159049
Contact name
Bruce Murray
Contact email
Sponsor organisation
Moletest (Scotland) Ltd
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
The clinical load on health services arising from cutaneous (skin) moles or lesions which may be suspicious of malignancy - malignant melanoma, squamous cell carcinoma and basal cell carcinoma - is substantial and growing. In the UK, melanoma is the third commonest cancer in women and fifth in men. Most moles are benign but nonetheless are a source of anxiety for patients until the diagnosis is known.
Moletest Limited has developed a photographic image analysis system based on an App using iPad technology aimed at discriminating benign pigmented skin lesions from those considered suspect for melanoma. The software creates numerate values for several defined characteristics of the image some of which are not apparent to the naked eye. Data have been accumulated using library images of benign and malignant lesions that demonstrate an ability to discriminate.
This is a study to evaluate the technology alongside normal clinical practice.The ultimate objective of the App is to provide a diagnostic aid for primary care use to reduce referrals to secondary care.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
15/EE/0097
Date of REC Opinion
27 Mar 2015
REC opinion
Further Information Favourable Opinion